OG
Therapeutic Areas
Aprea Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| APR-1051 | Advanced Solid Tumors (CCNE1/2, FBXW7, PPP2R1A altered; KRAS G12/13 & TP53 mutant CRC; HPV+ Oropharyngeal, Cervical, Vaginal, Vulvar SCC; Uterine Serous Carcinoma) | Phase 1 |
| ATRN-119 (Mosipasertib) | Advanced Solid Tumors (Ovarian, CRC, Lung) & Hematological Cancers (AML, MDS) with synthetic lethal alterations | Phase 1/2a |
| APR-1602 | Solid Tumors & Hematological Cancers | Preclinical |